GigaGen
  • Our Company
    • Team
    • News
  • Our Science
    • Surge and Magnify Technologies
    • Publications, Scientific Posters & Presentations
  • Pipeline
    • Oncology
    • Recombinant Polyclonals
  • Collaborations
  • Careers
  • Contact
  • Menu Menu

News Archive

GigaGen Receives NIH Grant to Develop Production Technology for Recombinant Intravenous Immunoglobulin

01/16/2018/by jkeller

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, has been awarded a $3 million grant from the National Institutes of Health (NIH) to advance its next-generation plasma therapy for patients with immune deficiencies. GigaGen will use the funds to develop a natural repertoire antibody protein expression system, laying the foundation for a recombinant immunoglobulin […]

Read more

GigaGen to Develop Human Antibodies Against 17 Immuno-oncology Targets

12/19/2017/by David Johnson

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the disclosure of 17 immuno-oncology targets the company is pursuing within their robust internal pipeline. GigaGen has completed a large discovery and development effort of fully human antibody drug candidates against the following cancer targets: PD-1, LAG-3, OX40, CSF1R, ICOS, VISTA, CD47, B7-H4, CD27, […]

Read more

GigaGen CEO David Johnson to Present at 2017 Antibody Engineering & Therapeutics Meeting

12/14/2017/by David Johnson

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present at the 2017 Antibody Engineering & Therapeutics Meeting. Dr. Johnson’s presentation will take place at 3:30 p.m. PST on December 15, 2017, at the Manchester Grand Hyatt in San Diego, Calif. Read the full press […]

Read more

GigaGen Studies Published in Peer-Reviewed Journal mAbs Validate Its Novel Monoclonal Antibody Discovery Approach in Mouse and Human Antibody Repertoires

08/29/2017/by David Johnson

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the publication of preclinical data validating its Surge™ discovery platform to rapidly interrogate and screen mouse and human antibody repertoires. The findings appear in two separate studies published online in the peer-reviewed scientific journal mAbs and will be available in print in the upcoming […]

Read more

GigaGen closes $50M deal with Grifols

07/21/2017/by David Johnson

GigaGen has received $35 million in investment funding and $15 million licensing fee payment from Grifols. Read the full story from Endpoints: An upstart in the polyclonal antibody biz just lined up $50M for its plan to disrupt a multibillion-dollar business

Read more

GigaGen and Trianni Announce License Agreement for Discovery of Fully Human Immuno-Oncology Antibodies

02/28/2017/by David Johnson

GigaGen Inc., a biopharmaceutical company with patented technology for discovery of antibody therapeutics from millions-diverse immune repertoires, today announced a strategic partnership with Trianni, Inc., a biotechnology company that has developed novel mouse strains genetically engineered to express human antibodies. The partnership will use GigaGen technology to discover immuno-oncology antibody therapeutics through The Trianni Mouse […]

Read more

GigaGen Announces $1.37M National Cancer Institute (NCI) Grant Award for Discovery and Development of New Oncology Therapies

11/01/2016/by David Johnson

GigaGen Inc., a biopharmaceutical company with patented technology for discovery of T cell receptor (TCR) and antibody drugs from immune repertoires, today announced that it has been awarded a $1.37 million Phase II grant from the National Cancer Institute (NCI) through the NIH Small Business Innovation Research (SBIR) program. The grant supports discovery and development […]

Read more

GigaGen CEO Dave Johnson on Biotech Nation Radio – Ep. 16-41

10/13/2016/by David Johnson

Listen to Moira Gunn’s interview with Dave Johnson, PhD, CEO of GigaGen on “Creating a Synthetic Immune System” on Biotech Nation Radio.

Read more

GigaGen to Present on Copying and Mining Immune Systems for Drug Discovery at the LakePharma Protein Engineering Symposium

10/05/2016/by David Johnson

GigaGen Inc., a biopharmaceutical company with patented technology for discovery of T cell receptor (TCR) and antibody drugs from human and mouse immune repertoires, today announced that Dave Johnson, Ph.D., CEO of GigaGen, will present a research and development update at the 2016 LakePharma Protein Engineering Symposium at the South San Francisco Conference Center in […]

Read more

GigaGen and Cellular Therapeutics Ltd Sign Collaboration for Novel TCR Discovery Directly from Patient’s T cells

09/27/2016/by David Johnson

GigaGen Inc., a biotechnology company with patented technology for discovery of T cell receptor (TCR) and antibody therapeutics from human immune repertoires, today announced a collaboration with Cellular Therapeutics Limited (CTL) to investigate TCR sequences in Tumor Infiltrating Lymphocytes (TIL) for therapeutic potential. CTL, based in Manchester, England, is an immuno-oncology company specializing in the […]

Read more

GigaGen Wins Best E-Poster Award at ESID for Presentation of Preclinical Data for Recombinant Intravenous Immunoglobulin (IVIG)

09/23/2016/by David Johnson

GigaGen’s CEO, Dave Johnson, PhD, won the Best E-Poster Award for his presentation on “Manufacturing and Preclinical Validation of Recombinant Intravenous Immunoglobulin for Primary Immunodeficiency” in the Immunoglobulin and Immunomodulatory Therapy session on September 23, 2016 at the 17th biennial meeting of the European Society for Immunodeficiencies (“ESID”) in Barcelona, Spain. For details of the […]

Read more

GigaGen Announces $1.5M NIH Grant Award for Development of Recombinant Intravenous Immunoglobulin

09/20/2016/by David Johnson

GigaGen Inc., the leading innovator in massively high-throughput immune repertoire single-cell sequencing and protein expression, today announced that it has been awarded a $1.5 million Phase II grant from the National Institutes of Health (NIH). The Phase II grant was awarded through the NIH Small Business Innovation Research (SBIR) program in from the National Institute […]

Read more

GigaGen Announces Issue of US Patent for Polyclonal Antibody Production

09/13/2016/by David Johnson

GigaGen Inc., the leading innovator in massively high-throughput immune repertoire single-cell sequencing and protein expression, today announces that the United States Patent and Trademark Office has issued U.S. Patent No. 9,422,547, covering protein expression methods for the production of polyclonal antibodies from natural immune repertoires. GigaGen has exclusive rights to the patented technology and is […]

Read more

GigaGen Highlighted in Biospace.com Story

04/19/2016/by David Johnson

GigaGen’s development of the world’s first synthetic immune system was covered recently in the Biospace.com story Bay Area’s GigaGen Develops Synthetic Immune System to Harness Antibodies.   According to the article, “The development of therapeutics that harness the body’s immune system has exploded in popularity among biotech companies with many investing heavily in research and […]

Read more

GigaGen Announces Successful Completion of Technical Goals on Four NIH Grant Projects

03/08/2016/by David Johnson

GigaGen Inc., a world leader in massively high-throughput immune repertoire single-cell sequencing and protein expression, today announced that it has achieved all of the technical goals for four Phase I grants from the National Institutes of Health (NIH). The Phase I grants were awarded through the NIH Small Business Innovation Research (SBIR) program in 2015 […]

Read more

GigaGen Highlighted in Genome Web

02/17/2016/by David Johnson

The potential of GigaGen’s single cell sequencing and expression platform to revolutionize immunotherapy drug development and target discovery was highlighted in the recent Genome Web story Expanding Single-Cell Technology, GigaGen Moves Forward in Drug Development Market.   According to the article:   “Single-cell analysis firm GigaGen has made a sharp turn in its business plans over […]

Read more
Page 4 of 41234

Latest Tweets

GigaGenFollow

GigaGen
GigaGen@gigageninc·
16 Apr

We are advancing an anti- #CTLA4 #antibody with a unique profile that has the potential to provide enhanced efficacy and reduced toxicity against #tumors. Learn more here: https://bit.ly/3tlV5vg

Reply on Twitter 1383042739969867778Retweet on Twitter 1383042739969867778Like on Twitter 13830427399698677781Twitter 1383042739969867778
GigaGen@gigageninc·
15 Apr

Today we published research on our recombinant hyperimmune globulins in @NatureBiotech The data describe our proprietary technology used for the production of a new class of #antibody drugs, including our novel #COVID19 therapy. Read more: https://bit.ly/3ge9XbK

Reply on Twitter 1382729196217196546Retweet on Twitter 13827291962171965462Like on Twitter 13827291962171965467Twitter 1382729196217196546
GigaGen@gigageninc·
23 Mar

Today we announced we’ll be presenting a poster at @AACR Virtual Annual Meeting highlighting data that support the potential of dual PD-L1/TGF- β blockade to overcome resistance to first generation #oncology immunotherapies. Learn more: https://bit.ly/3seKkLp #AACR2021

Reply on Twitter 1374363950926737409Retweet on Twitter 13743639509267374091Like on Twitter 13743639509267374095Twitter 1374363950926737409
GigaGen@gigageninc·
9 Mar

Today Grifols announced its acquisition of GigaGen, which will support our novel method to generate a wide range of antibodies. GigaGen is currently developing the first recombinant polyclonal immunoglobulins & a portfolio of IO therapies. Read more: https://bit.ly/3quzRcZ

Reply on Twitter 1369381642985431045Retweet on Twitter 13693816429854310457Like on Twitter 13693816429854310459Twitter 1369381642985431045
GigaGen@gigageninc·
8 Mar

Today is #InternationalWomensDay2021! Thank you to our wonderful team of women at GigaGen for all of the contributions you’ve made both at our company and as #WomeninSTEM.

Reply on Twitter 1368924946097922054Retweet on Twitter 13689249460979220543Like on Twitter 13689249460979220543Twitter 1368924946097922054
© Copyright 2020 GigaGen. All Rights Reserved.
  • Twitter
  • LinkedIn
Scroll to top